Anupam Rasayan completes the Bliss GVS purchase: ₹299 a share for 48.2%, funded mostly by outside investors

At 7:53 pm on Monday, September 28 — after the market had closed — Anupam Rasayan filed a press release announcing that it has paid the consideration for a 48.2% controlling stake in Bliss GVS Pharma at ₹299 per share. The filing calls it the company's third strategic inorganic transaction, after Tanfac Industries (2022) and Jayhawk Fine Chemicals (February 2026), and the one that takes a custom-synthesis and specialty-chemicals maker into finished dosage formulations. The scale is what makes it worth studying: the stated funding of roughly ₹1,750 crore is about 13% of Anupam Rasayan's own ₹13,515 crore market capitalisation, and most of that money is not the company's.

The funding split deserves attention. Of the roughly ₹1,750 crore deployed (the sum of the two components the filing states), only ₹300 crore is conventional term debt — raised as secured NCDs at the subsidiary, Mates Visa Consultancy (MVCPL), which Anupam has unconditionally and irrevocably guaranteed, adding up to ₹300 crore plus interest and costs as a contingent liability on the parent's own balance sheet. The larger ~₹1,450 crore came from outside financial investors through instruments the press release describes as non-controlling and non-voting; the underlying filing shows MVCPL raises this balance through equity-like instruments issued to Purebliss Pharma Solutions, in which Anupam holds a pledged 15% stake. That filing also discloses one exit mechanic: Anupam has granted Purebliss an irrevocable option to buy 100% of MVCPL — the vehicle holding the Bliss GVS stake — for ₹1, exercisable if the financing hits default trigger events. The pricing, tenor and return terms of the ~₹1,450 crore of investor instruments are still not stated in this record, even though the enforcement structure around them now is.

The closing did not arrive unannounced on the exchange tape. In the days before the press release, a sequence of filings assembled the financing at the acquisition vehicle: a board meeting approved execution of security documents for financing being availed by Mates Visa Consultancy — the same subsidiary that made the acquisition — including a proposed issuance of up to ₹300 crore of senior secured NCDs at that subsidiary, with proceeds earmarked for the acquisition of Bliss GVS Pharma securities by the subsidiary. Days later came the execution of the debenture trust deed and the deed of pledge completing that structure. Read together (an inference, but a documented one), the paper trail shows the acquisition vehicle being funded in public view before the consideration was paid.

1. 16 Sept

   Board meeting called for Sep 19 to consider raising up to ₹160 Cr via secured, rated, unlisted, redeemable NCDs on private placement.

2. 17 Sept

   Board approves execution of transaction and security documents for financing availed by wholly owned subsidiary Mates Visa Consultancy (MVCPL), which proposes to issue up to 30,000 senior secured unrated unlisted redeemable NCDs of ₹1 lakh face value each — up to ₹300 Cr. Next session's close: +2.1%.

3. 19 Sept

   Board approves the parent's issuance of up to 16,000 NCDs of ₹1 lakh each, aggregating not more than ₹160 Cr, in a single tranche. Filed Saturday night; the next session (Sep 21) closed −3.9%.

4. 23 Sept

   Debenture trust deed executed with MVCPL and Catalyst Trusteeship as debenture trustee, along with an unattested deed of pledge and power of attorney. Next session's close: −1.4%.

5. 28 Sept

   Press release: consideration paid, acquisition of the 48.2% stake concluded. Filed at 7:53 pm, after close.

Bliss GVS Pharma, founded in 1984, is a branded formulations company with more than 150 brands across anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, anti-diabetic and cardiovascular therapies. It operates six manufacturing facilities in Maharashtra certified to US FDA, EU-GMP and WHO-GMP standards, and the press release notes it is India's first EU-GMP certified suppositories manufacturer. The number that carries the growth argument: manufacturing infrastructure currently operating at approximately 30% capacity utilisation. The company's case, stated plainly in the filing, is that it bought an installed, certified plant network running at less than a third of capacity — the upside is filling it. Whether that happens is execution, not arithmetic.

The three deals form a deliberate sequence, and the press release frames them that way. Tanfac (a 24.96% stake with management control acquired in 2022, followed by an open offer, and topped up as recently as September 9 this year with a ₹60.88 crore preferential allotment at ₹2,341 per share) secured fluorine-based raw materials. Jayhawk — 100% acquired in February 2026 at an enterprise value of approximately US$134 million — put manufacturing in Kansas, closer to developed-market customers, and contributed roughly 20–22% of consolidated revenue in Q1 FY27 at 19–20% EBITDA margins per the release. Bliss GVS now extends the chain forward into finished dosages. Raw materials, global manufacturing, formulations: each deal bought a stage of the value chain rather than more of the same.

Q1 FY27 consolidated revenue of ₹654.98 crore grew 34.8% over the ₹485.83 crore of Q1 FY26, with operating margin at 24.8% and net profit of ₹51.2 crore. The line to keep an eye on is interest: ₹49.2 crore in Q1 FY27 against ₹35.7 crore a year earlier — up 37.9% — and that is before the ₹300 crore of acquisition debt raised at the subsidiary, Mates Visa Consultancy — the same amount the press release calls a "term loan" — and the parent's separate ₹160 crore NCD, whose proceeds are earmarked partly for repayment of existing debt facilities per the September 19 filing, enter the accounts. The press release argues the investor-funded structure preserves balance-sheet capacity; the existing P&L shows a finance cost line that was already growing faster than revenue. Both statements can be true at once, which is precisely why the terms of the ~₹1,450 crore of investor instruments matter.

The stock closed September 28 at ₹1,187.10 — 16.1% below its adjusted 52-week high of ₹1,415 set on May 7, and 13.6% above the ₹1,045.20 low of last September. The loudest session in the window was September 21: a −3.9% close at ₹1,160.80 on 60.3 lakh shares, by far the heaviest volume of the last sixty sessions. It was the first session after the Saturday-night NCD approval, and the same day the exchange recorded a bulk sale of 15.02 lakh shares by Ashapura Commodities at ₹1,165.16 and a bulk purchase of 9 lakh shares by 360 ONE PIPE Fund at ₹1,165.00 — the record shows the coincidence of these events, not which one drove the price. Ownership has been steady where it is disclosed: promoters held 59.07% at both the March and June quarter-ends, while FII holdings rose from 78.6 lakh to 87.8 lakh shares over the same interval. The completion press release itself landed after Monday's close, so the ₹1,187.10 close does not price it — September 29 is the first session that can.